Active Ingredient History
Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection by an ophthalmologist. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Macular Edema (approved 2022)
Wet Macular Degeneration (approved 2022)
Choroidal Neovascularization (Phase 2)
Diabetic Retinopathy (Phase 2)
Macular Degeneration (Phase 4)
Macular Edema (Phase 4)
Neovascularization, Pathologic (Phase 3)
Retinal Diseases (Phase 3)
Retinal Vein Occlusion (Phase 3)
Wet Macular Degeneration (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
